Comparative Pharmacology
Head-to-head clinical analysis: THEOCLEAR L A 130 versus XOPENEX HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THEOCLEAR L A 130 versus XOPENEX HFA.
THEOCLEAR L.A.-130 vs XOPENEX HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
Selective beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing intracellular cyclic AMP via activation of adenylyl cyclase.
130 mg orally every 12 hours; extended-release tablet.
2 inhalations (90 mcg each) every 4-6 hours as needed via oral inhalation. Maximum 12 inhalations per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
Terminal elimination half-life: 3-4 hours; clinical context: dosing every 4-6 hours for bronchodilation
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
Renal: 80-100% as unchanged drug and metabolites; fecal: minimal (<5%)
Category C
Category C
Bronchodilator
Bronchodilator